Sourav Nath
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sourav Nath has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Suman Adhikari
Department of Chemistry, Govt. Degree College, Dharmanagar, Tripura (N)-799253, India
5 shared publications - Akalesh Kumar Verma
Department of Zoology, Cell & Biochemical Technology Laboratory, Cotton University, Guwahati 781001, Assam, India
2 shared publications - Arijit Das
Department of Chemistry, Bir Bikram Memorial College, Agartala, Tripura (W), India
2 shared publications - Nabajyoti Baildya
University of Kalyani
2 shared publications - Sourav Roy
Department of Biochemistry and Molecular Biophysics Manhattan Kansas USA
2 shared publications - Subhadip Roy
Department of Chemistry, The ICFAI University Tripura, Agartala, Tripura 799210, India
2 shared publications
Latest Publications
- Open Access
- 3 March 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (14) , 12547-12557
Crystallographic and computational investigation of a bent-core Schiff base Ni( ii ) complex with DNA and protein binding studies
The rational design and synthesis of a three-ring bent-core Schiff base ligand, ( E )-4-(trifluoromethyl)phenyl-3-((4-butoxy-2-hydroxybenzylidene)amino)-2-methylbenzoate (HL), and its mononuclear Ni( ii ) complex, [Ni(L) 2 ] (1), are described.
- 3 March 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (14) , 12547-12557
Open AccessCrystallographic and computational investigation of a bent-core Schiff base Ni( ii ) complex with DNA and protein binding studies
The rational design and synthesis of a three-ring bent-core Schiff base ligand, ( E )-4-(trifluoromethyl)phenyl-3-((4-butoxy-2-hydroxybenzylidene)amino)-2-methylbenzoate (HL), and its mononuclear Ni( ii ) complex, [Ni(L) 2 ] (1), are described.
- 26 August 2025
- Published by Wiley in Journal of Heterocyclic Chemistry
- Vol. 62 (11) , 1378-1389
Synthesis, Crystal Structure, Theoretical Analysis, Anticancer Properties, and Molecular Docking Study of a Dipyridyl Thiourea Compound
In our pursuit of developing effective anticancer drugs, a dipyridyl thiourea derivative ( 1 ) was designed and synthesized via a one‐pot reaction at room temperature. The structure of the synthesized compound was confirmed using FT‐IR, 1 H NMR, mass spectrometry, elemental analysis, and single‐crystal X‐ray crystallography. Both 1 H NMR spectral analysis and single‐crystal X‐ray analysis revealed the formation of strong intramolecular hydrogen bonds in 1 . Hirshfeld surface analysis was also employed to quantify various interactions within the structure. Density Functional Theory (DFT) calculations, performed at the B3LYP/6‐31G(d) level with solvent effects in THF, revealed a planar geometry favoring π⋯π stacking. The HOMO–LUMO gap of 4.58 eV indicated moderate reactivity and good charge delocalization. HOMO charge density was localized on the sulfur atom, while LUMO was delocalized across the aromatic core. The cytotoxic potential of compound 1 was assessed using the Trypan Blue exclusion assay against Dalton's Lymphoma (DL) cells, a murine T‐cell lymphoma model, revealing a dose‐dependent inhibition with an IC 50 of 22.5 μM. Furthermore, minimal cytotoxicity was observed in normal peripheral blood mononuclear cells (PBMCs), highlighting the selectivity of 1 . Moreover, molecular docking studies further demonstrated favorable binding of compound 1 at the trimeric interface of mouse tumor necrosis factor, stabilized predominantly by hydrophobic interactions and a few hydrogen bonds. These findings collectively support the potential of 1 as a selective anticancer agent, warranting further biological validation.
- 26 August 2025
- Published by Wiley in Journal of Heterocyclic Chemistry
- Vol. 62 (11) , 1378-1389
Synthesis, Crystal Structure, Theoretical Analysis, Anticancer Properties, and Molecular Docking Study of a Dipyridyl Thiourea Compound
In our pursuit of developing effective anticancer drugs, a dipyridyl thiourea derivative ( 1 ) was designed and synthesized via a one‐pot reaction at room temperature. The structure of the synthesized compound was confirmed using FT‐IR, 1 H NMR, mass spectrometry, elemental analysis, and single‐crystal X‐ray crystallography. Both 1 H NMR spectral analysis and single‐crystal X‐ray analysis revealed the formation of strong intramolecular hydrogen bonds in 1 . Hirshfeld surface analysis was also employed to quantify various interactions within the structure. Density Functional Theory (DFT) calculations, performed at the B3LYP/6‐31G(d) level with solvent effects in THF, revealed a planar geometry favoring π⋯π stacking. The HOMO–LUMO gap of 4.58 eV indicated moderate reactivity and good charge delocalization. HOMO charge density was localized on the sulfur atom, while LUMO was delocalized across the aromatic core. The cytotoxic potential of compound 1 was assessed using the Trypan Blue exclusion assay against Dalton's Lymphoma (DL) cells, a murine T‐cell lymphoma model, revealing a dose‐dependent inhibition with an IC 50 of 22.5 μM. Furthermore, minimal cytotoxicity was observed in normal peripheral blood mononuclear cells (PBMCs), highlighting the selectivity of 1 . Moreover, molecular docking studies further demonstrated favorable binding of compound 1 at the trimeric interface of mouse tumor necrosis factor, stabilized predominantly by hydrophobic interactions and a few hydrogen bonds. These findings collectively support the potential of 1 as a selective anticancer agent, warranting further biological validation.
- Open Access
- 30 April 2025
- Published by International Academic Publishing House in INTERNATIONAL JOURNAL OF EXPERIMENTAL RESEARCH AND REVIEW
- Vol. 47, 120-132
Recent Advances in Metal-based Drugs in Cancer Therapy
The distinctive attributes of metals, for example, their redox activity, varied coordination modes, and reactivity against biomolecules have drawn a lot of attention to the therapeutic potential of metal complexes against various diseases. These characteristics make them a desirable probe for the development of metallodrugs that bind to the targeted biomolecules selectively and change the cellular mechanism of proliferation. Metal-based drugs have appeared as propitious candidates for cancer treatment attributable to their exceptional structural features and versatile modes of action. Recently, a substantial advancement has been made in the development of metal-based compounds with enhanced effectiveness and reduced toxicity profiles. Numerous metallodrugs have been assessed both in vitro and in vivo, with a few even progressing to clinical trials. Nevertheless, it is still challenging to find novel chemical formulations and therapeutic approaches that can specifically target cancer cells while sparing healthy cells. For many types of cancer, there are still few treatment choices available, despite advancements that have been directed to the design of novel therapeutics. This review article provides an outline of the up-to-date advancements in the field of metallodrugs for cancer treatment.
- 30 April 2025
- Published by International Academic Publishing House in INTERNATIONAL JOURNAL OF EXPERIMENTAL RESEARCH AND REVIEW
- Vol. 47, 120-132
Open AccessRecent Advances in Metal-based Drugs in Cancer Therapy
The distinctive attributes of metals, for example, their redox activity, varied coordination modes, and reactivity against biomolecules have drawn a lot of attention to the therapeutic potential of metal complexes against various diseases. These characteristics make them a desirable probe for the development of metallodrugs that bind to the targeted biomolecules selectively and change the cellular mechanism of proliferation. Metal-based drugs have appeared as propitious candidates for cancer treatment attributable to their exceptional structural features and versatile modes of action. Recently, a substantial advancement has been made in the development of metal-based compounds with enhanced effectiveness and reduced toxicity profiles. Numerous metallodrugs have been assessed both in vitro and in vivo, with a few even progressing to clinical trials. Nevertheless, it is still challenging to find novel chemical formulations and therapeutic approaches that can specifically target cancer cells while sparing healthy cells. For many types of cancer, there are still few treatment choices available, despite advancements that have been directed to the design of novel therapeutics. This review article provides an outline of the up-to-date advancements in the field of metallodrugs for cancer treatment.
- 8 November 2024
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 39 (2)
Supramolecular Co (II) Complex Fabricated From Adenine Derivative: Synthesis, Crystal Structure, Hirshfeld Surface, DFT Optimization, Anticancer, and Molecular Docking Studies
This article presents the synthesis of a novel mononuclear Co (II) complex [ Co(9‐BuA) 2 Cl 2 ] (1) , its characterization, supramolecular packing pattern, theoretical calculations, anticancer properties, and molecular docking studies. Complex 1 was generated from 9‐butyl adenine ( 9‐BuA ) building block and characterized by spectroscopic methods (FT‐IR, mass, elemental analysis) and single crystal X‐ray diffraction analysis. The cobalt (II) ion in complex 1 is distorted in its tetrahedral environment. The Co +2 is coordinated to the two rare N1 binding sites of the pyrimidinate moiety of two 9‐BuA ligands and two chlorine atoms occupying the axial positions. Both intramolecular and intermolecular hydrogen bonds support the formation of supramolecular assembly and stabilize the crystal structure. The nature of the intermolecular interactions in the supramolecular network was also decoded by Hirshfeld surface analysis and molecular surface contours ( d norm ). The percentage contributions are represented by 2D fingerprint plots. The average energy between dimers was determined by the energy framework analysis, and the crystal packing's three‐dimensional topology was also investigated. Density functional theory (DFT) has been used to ascertain the geometry and interactions in the complex. The cytotoxic effects of Co (II) complex 1 and corresponding 9‐BuA ligand were investigated in Dalton's lymphoma (DL) malignant cancer cells and on normal peripheral blood mononuclear cells (PBMCs) to evaluate their anticancer activity. Finally, molecular docking analyses have been carried out to analyze the nature of molecular interactions between Co (II) complex 1 and the receptor.
- 8 November 2024
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 39 (2)
Supramolecular Co (II) Complex Fabricated From Adenine Derivative: Synthesis, Crystal Structure, Hirshfeld Surface, DFT Optimization, Anticancer, and Molecular Docking Studies
This article presents the synthesis of a novel mononuclear Co (II) complex [ Co(9‐BuA) 2 Cl 2 ] (1) , its characterization, supramolecular packing pattern, theoretical calculations, anticancer properties, and molecular docking studies. Complex 1 was generated from 9‐butyl adenine ( 9‐BuA ) building block and characterized by spectroscopic methods (FT‐IR, mass, elemental analysis) and single crystal X‐ray diffraction analysis. The cobalt (II) ion in complex 1 is distorted in its tetrahedral environment. The Co +2 is coordinated to the two rare N1 binding sites of the pyrimidinate moiety of two 9‐BuA ligands and two chlorine atoms occupying the axial positions. Both intramolecular and intermolecular hydrogen bonds support the formation of supramolecular assembly and stabilize the crystal structure. The nature of the intermolecular interactions in the supramolecular network was also decoded by Hirshfeld surface analysis and molecular surface contours ( d norm ). The percentage contributions are represented by 2D fingerprint plots. The average energy between dimers was determined by the energy framework analysis, and the crystal packing's three‐dimensional topology was also investigated. Density functional theory (DFT) has been used to ascertain the geometry and interactions in the complex. The cytotoxic effects of Co (II) complex 1 and corresponding 9‐BuA ligand were investigated in Dalton's lymphoma (DL) malignant cancer cells and on normal peripheral blood mononuclear cells (PBMCs) to evaluate their anticancer activity. Finally, molecular docking analyses have been carried out to analyze the nature of molecular interactions between Co (II) complex 1 and the receptor.
- Open Access
- 30 March 2024
- Published by International Academic Publishing House in INTERNATIONAL JOURNAL OF EXPERIMENTAL RESEARCH AND REVIEW
- Vol. 37, 159-173
Metal-Based Drugs in Cancer Therapy
Metal-based drugs have emerged as pivotal therapeutics in cancer therapy, enlightening a path toward innovative and effective treatment strategies. Platinum-based therapeutics, notably cisplatin, carboplatin, and oxaliplatin, have transformed the landscape of cancer treatment, setting the stage for the development of next-generation metal-based compounds. Delving into the principles governing the design of metal-based drugs, this article navigates through their intricate coordination chemistry, targeted delivery approaches, and mechanisms of action. Notably, metal-based compounds form covalent bonds with DNA, disrupting vital cellular processes and inducing apoptosis in cancerous tissues. Even though contemporary chemotherapy as well as radiotherapeutic methods have greatly increased patient survival rates, disease recurrence still represents a fatal danger. The probability of metastasis and the drug resistance are increased by the incomplete clearance of neoplastic tissues from the body. This review explores the compelling journey of metal-based compounds, from their historical significance in ancient remedies to their pivotal role in modern oncology, and also discusses the recent advancements and emerging trends that promise to shape the future of metallodrugs. The shining promise of metal-based drugs in cancer remedies holds the potential to revolutionize treatment paradigms, offering hope and resilience in the ongoing battle against one of humanity's most relentless adversaries.
- 30 March 2024
- Published by International Academic Publishing House in INTERNATIONAL JOURNAL OF EXPERIMENTAL RESEARCH AND REVIEW
- Vol. 37, 159-173
Open AccessMetal-Based Drugs in Cancer Therapy
Metal-based drugs have emerged as pivotal therapeutics in cancer therapy, enlightening a path toward innovative and effective treatment strategies. Platinum-based therapeutics, notably cisplatin, carboplatin, and oxaliplatin, have transformed the landscape of cancer treatment, setting the stage for the development of next-generation metal-based compounds. Delving into the principles governing the design of metal-based drugs, this article navigates through their intricate coordination chemistry, targeted delivery approaches, and mechanisms of action. Notably, metal-based compounds form covalent bonds with DNA, disrupting vital cellular processes and inducing apoptosis in cancerous tissues. Even though contemporary chemotherapy as well as radiotherapeutic methods have greatly increased patient survival rates, disease recurrence still represents a fatal danger. The probability of metastasis and the drug resistance are increased by the incomplete clearance of neoplastic tissues from the body. This review explores the compelling journey of metal-based compounds, from their historical significance in ancient remedies to their pivotal role in modern oncology, and also discusses the recent advancements and emerging trends that promise to shape the future of metallodrugs. The shining promise of metal-based drugs in cancer remedies holds the potential to revolutionize treatment paradigms, offering hope and resilience in the ongoing battle against one of humanity's most relentless adversaries.